fashion -WSS

fashion

author：fashion 2025-09-30 22:28:25 - browse：95

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Living with Hashimoto's and celiac disease, and med school, too

knowledge

focus

WSS

Bring on the sabbaticals for nurses

Pregnancy ages women, but effects reverse after delivery

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

What Kate Middleton's cancer revelation might teach the world

This gene therapy has record $4.25 million price. It's saved children.

explore

fashion

knowledge

Medical records are filled with copy

This gene therapy has record $4.25 million price. It's saved children.

After affirmative action ruling, medical educators look to 'holistic review'

Mirador, a new biotech startup, launches with $400 million

Malaria cases in Florida and Texas: Here’s what you need to know

Texas board proposes rules on abortion law emergency exemption

Drug repurposing or repositioning? The language matters

Pregnancy ages women, but effects reverse after delivery

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Adam's Take: Intra

entertainment

Living with Hashimoto's and celiac disease, and med school, too

Medical devices makers are asking for forgiveness, not permission

New details revealed about Purdue's marketing of OxyContin

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Biotech investment managers search for lucrative opportunities

The pain doctors face in trying to build their families

knowledge

focus

focus

hotspot